Attorney's Docket No.: 14875-134US1 / C1-A0203P-US

Applicant: Tetsuo Kojima Serial No.: Unassigned Filed: Herewith Page: 3 of 7

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

- 1. (Original) A gene encoding two antibody variable domains, wherein the two antibody variable domains are connected by a linker comprising a restriction enzyme site.
- 2. (Original) The gene of claim 1, wherein the linker comprises two or more restriction enzyme sites.
- 3. (Currently Amended) The gene of claim 1 [[or 2]], wherein one of the two antibody variable domains is a heavy chain variable domain and the other is a light chain variable domain.
- 4. (Currently Amended) The gene of any one of claims 1 to 3 claim 1, wherein the two antibody variable domains are connected by a long linker.
- 5. (Original) A gene encoding two antibody variable domains, where both ends comprise a restriction enzyme site.
- 6. (Original) The gene of claim 5, wherein one of the two antibody variable domains is a heavy chain variable domain and the other is a light chain variable domain.
- 7. (Currently Amended) The gene of claim 5 [[or 6]], wherein the two nucleotides encoding the two antibody variable domains are connected with a long linker.
- 8. (Original) A gene encoding four antibody variable domains, wherein the gene comprises a restriction enzyme site between the first and second antibody variable domains, and between the third and fourth antibody variable domains.

Applicant: Tetsuo Kojima Attorney's Docket No.: 14875-134US1 / C1-A0203P-US

Serial No.: Unassigned Filed: Herewith Page: 4 of 7

9. (Original) The gene of claim 8, wherein the first and second antibody variable domains are connected with a short linker, the third and fourth domains are connected with a short linker, and the second and third antibody variable domains are connected with a long linker.

- 10. (Currently Amended) The gene of claim 8 [[or 9]], wherein the four antibody variable domains are a heavy chain variable domain and a light chain variable domain directed against a first antigen, and a heavy chain variable domain and a light chain variable domain directed against a second antigen.
- 11. (Original) The gene of claim 10, wherein the four antibody variable domains are comprised in the order: a light chain variable domain against the first antigen, a heavy chain variable domain directed against the second antigen, a light chain variable domain against the second antigen, and a heavy chain variable domain against the first antigen.
- 12. (Currently Amended) A method for constructing a gene encoding a bispecific single chain diabody, wherein the method comprises:
 - (a) treating the gene of any one of claims 1 to 4 claim 1 with a restriction enzyme;
- (b) treating the gene of any one of claims 5 to 7 a gene encoding two antibody variable domains, where both ends comprise a restriction enzyme site, with a restriction enzyme; and
 - (c) inserting the gene constructed in step (b) into the gene constructed in step (a).
 - 13. (Currently Amended) A peptide encoded by a gene of any of claims 1 to 11 claim 1.
- 14. (Currently Amended) An antibody library comprising a gene of any of claims 1 to 11 claim 1.

Applicant: Tetsuo Kojima Attorney's Docket No.: 14875-134US1 / C1-A0203P-US

Serial No.: Unassigned
Filed: Herewith
Page: 5 of 7

15. (Original) A method for constructing an antibody library or expression vector, wherein the method comprises:

- (a) constructing an antibody phage library in which a light chain variable domain and a heavy chain variable domain, both directed against a first antigen, are connected with a long linker comprising a restriction enzyme site;
- (b) constructing an antibody phage library in which a light chain variable region and a heavy chain variable domain, both directed against a second antigen, are connected with a long linker at one end, where the other ends comprise a restriction enzyme site;
- (c) treating the phage libraries constructed in steps (a) and (b), or genes comprising the variable domains prepared from these phage libraries, with a restriction enzyme; and
- (d) performing ligation of the fragments obtained from the above treatment to construct a fragment in which the heavy and light chain variable domains against the second antigen are inserted between the light and heavy chain variable domains against the first antigen.
- 16. (Currently Amended) A method for constructing an antibody library or expression vector, wherein the method comprises:
 - (a) treating the gene of any one of claims 1 to 4 claim 1 with a restriction enzyme;
- (b) treating the gene of any one of claims 5 to 7 a gene encoding two antibody variable domains, where both ends comprise a restriction enzyme site, with a restriction enzyme; and
 - (c) inserting the gene constructed in step (b) into the gene constructed in step (a).
- 17. (Original) A method for constructing an antibody library or expression vector, wherein the method comprises:
- (a) constructing an antibody phage library in which a light chain variable domain and a heavy chain variable domain, both against an antigen, are connected with a long linker comprising two or more restriction enzyme sites;
- (b) treating the above phage library, or genes comprising variable domains prepared from the phage library, with a restriction enzyme; and

Applicant: Tetsuo Kojima Attorney's Docket No.: 14875-134US1 / C1-A0203P-US

Serial No.: Unassigned
Filed: Herewith
Page: 6 of 7

(c) performing self-ligation of the fragments obtained above to shorten the linker between the variable domains.

18. (Currently Amended) An expression vector comprising a gene of any one of claims

1 to 11 claim 1.